MannKind Corp
MNKD5.790USD
-0.140-2.36%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.78BMarket Cap
59.02P/E TTM
More Details of MannKind Corp Company
MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
MannKind Corp Info
Ticker SymbolMNKD
Company nameMannKind Corp
IPO dateJul 28, 2004
CEOCastagna (Michael E)
Number of employees407
Security typeOrdinary Share
Fiscal year-endJul 28
Address1 Casper Street
CityDANBURY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code06810
Phone18186615000
Websitehttps://mannkindcorp.com/
Ticker SymbolMNKD
IPO dateJul 28, 2004
CEOCastagna (Michael E)
Company Executives of MannKind Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Michael E. Castagna, Pharm.D.
Dr. Michael E. Castagna, Pharm.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.71M
--
Dr. David B. Thomson, J.D., Ph.D.
Dr. David B. Thomson, J.D., Ph.D.
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
621.22K
--
Mr. Steven B. Binder
Mr. Steven B. Binder
Director
Director
452.01K
-17.33%
Mr. Dominic (Nick) Marasco
Mr. Dominic (Nick) Marasco
President, Endocrine Business Unit
President, Endocrine Business Unit
333.43K
+32.31%
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Independent Director
Independent Director
201.15K
+14.19%
Mr. Ronald J. Consiglio
Mr. Ronald J. Consiglio
Independent Director
Independent Director
118.43K
--
Ms. Jennifer Grancio
Ms. Jennifer Grancio
Independent Director
Independent Director
110.70K
--
Dr. Sabrina Kay
Dr. Sabrina Kay
Independent Director
Independent Director
107.03K
--
Ms. Christine Mundkur, J.D.
Ms. Christine Mundkur, J.D.
Independent Director
Independent Director
27.68K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
24.46K
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Michael E. Castagna, Pharm.D.
Dr. Michael E. Castagna, Pharm.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.71M
--
Dr. David B. Thomson, J.D., Ph.D.
Dr. David B. Thomson, J.D., Ph.D.
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
621.22K
--
Mr. Steven B. Binder
Mr. Steven B. Binder
Director
Director
452.01K
-17.33%
Mr. Dominic (Nick) Marasco
Mr. Dominic (Nick) Marasco
President, Endocrine Business Unit
President, Endocrine Business Unit
333.43K
+32.31%
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Independent Director
Independent Director
201.15K
+14.19%
Mr. Ronald J. Consiglio
Mr. Ronald J. Consiglio
Independent Director
Independent Director
118.43K
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
Product sales
44.68M
58.38%
Royalties
31.23M
40.81%
Services
621.00K
0.81%
By RegionUSD
Name
Revenue
Proportion
United States
76.53M
100.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Product sales
44.68M
58.38%
Royalties
31.23M
40.81%
Services
621.00K
0.81%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
7.60%
The Vanguard Group, Inc.
5.72%
Rubric Capital Management LP
3.72%
State Street Investment Management (US)
3.50%
Geode Capital Management, L.L.C.
2.41%
Other
77.06%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
7.60%
The Vanguard Group, Inc.
5.72%
Rubric Capital Management LP
3.72%
State Street Investment Management (US)
3.50%
Geode Capital Management, L.L.C.
2.41%
Other
77.06%
Shareholder Types
Shareholders
Proportion
Investment Advisor
22.92%
Investment Advisor/Hedge Fund
18.18%
Hedge Fund
11.21%
Research Firm
3.79%
Individual Investor
1.82%
Bank and Trust
0.63%
Pension Fund
0.30%
Insurance Company
0.03%
Other
41.12%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
473
171.20M
55.75%
-15.78M
2025Q2
477
184.37M
60.10%
+2.23M
2025Q1
482
184.47M
60.73%
+2.52M
2024Q4
470
175.08M
57.68%
+5.91M
2024Q3
459
161.03M
58.24%
+6.62M
2024Q2
442
145.29M
52.88%
-4.76M
2024Q1
433
140.98M
52.03%
-8.31M
2023Q4
422
141.98M
52.59%
-12.51M
2023Q3
418
148.17M
55.00%
-3.06M
2023Q2
412
143.59M
53.56%
-12.28M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
23.58M
7.69%
+2.13M
+9.93%
Jun 30, 2025
The Vanguard Group, Inc.
18.10M
5.9%
+838.68K
+4.86%
Jun 30, 2025
State Street Investment Management (US)
10.75M
3.5%
+1.28M
+13.47%
Jun 30, 2025
Geode Capital Management, L.L.C.
7.62M
2.48%
+831.48K
+12.25%
Jun 30, 2025
Nitorum Capital, L.P.
7.01M
2.29%
-774.19K
-9.94%
Jun 30, 2025
UBS Financial Services, Inc.
2.11M
0.69%
-4.40M
-67.61%
Jun 30, 2025
Avoro Capital Advisors LLC
5.85M
1.91%
-2.90M
-33.14%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
4.05M
1.32%
+528.66K
+15.00%
Jun 30, 2025
Two Sigma Investments, LP
5.91M
1.93%
-1.19M
-16.80%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Invesco Biotechnology & Genome ETF
3.65%
ALPS Medical Breakthroughs ETF
0.74%
Invesco NASDAQ Future Gen 200 ETF
0.65%
VictoryShares Small Cap Free Cash Flow ETF
0.49%
Global X Aging Population ETF
0.33%
First Trust Small Cap Growth AlphaDEX Fund
0.28%
State Street SPDR S&P Biotech ETF
0.28%
State Street SPDR S&P Kensho New Econ Comp ETF
0.27%
Direxion Daily S&P Biotech Bull 3X Shares
0.18%
ProShares Ultra Nasdaq Biotechnology
0.17%
View more
Invesco Biotechnology & Genome ETF
Proportion3.65%
ALPS Medical Breakthroughs ETF
Proportion0.74%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.65%
VictoryShares Small Cap Free Cash Flow ETF
Proportion0.49%
Global X Aging Population ETF
Proportion0.33%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.28%
State Street SPDR S&P Biotech ETF
Proportion0.28%
State Street SPDR S&P Kensho New Econ Comp ETF
Proportion0.27%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.18%
ProShares Ultra Nasdaq Biotechnology
Proportion0.17%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of MannKind Corp?
The top five shareholders of MannKind Corp are:
BlackRock Institutional Trust Company, N.A. holds 23.58M shares, accounting for 7.69% of the total shares.
The Vanguard Group, Inc. holds 18.10M shares, accounting for 5.90% of the total shares.
State Street Investment Management (US) holds 10.75M shares, accounting for 3.50% of the total shares.
Geode Capital Management, L.L.C. holds 7.62M shares, accounting for 2.48% of the total shares.
Nitorum Capital, L.P. holds 7.01M shares, accounting for 2.29% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 23.58M shares, accounting for 7.69% of the total shares.
The Vanguard Group, Inc. holds 18.10M shares, accounting for 5.90% of the total shares.
State Street Investment Management (US) holds 10.75M shares, accounting for 3.50% of the total shares.
Geode Capital Management, L.L.C. holds 7.62M shares, accounting for 2.48% of the total shares.
Nitorum Capital, L.P. holds 7.01M shares, accounting for 2.29% of the total shares.
What are the top three shareholder types of MannKind Corp?
The top three shareholder types of MannKind Corp are:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Rubric Capital Management LP
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Rubric Capital Management LP
How many institutions hold shares of MannKind Corp (MNKD)?
As of 2025Q3, 473 institutions hold shares of MannKind Corp, with a combined market value of approximately 171.20M, accounting for 55.75% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -4.35%.
What is the biggest source of revenue for MannKind Corp?
In FY2025Q2, the Product sales business generated the highest revenue for MannKind Corp, amounting to 44.68M and accounting for 58.38% of total revenue.
